Sanofi and Sobi’s Efanesoctocog Alfa (BIVV001) Report the US FDA Acceptance for Priority Review of BLA to Treat Hemophilia A
Shots:
- The BLA was based on the P-III (XTEND-1) study evaluating efanesoctocog alfa (qw) in 159 patients aged ≥12yrs. with sev. hemophilia A prior treated with factor VIII replacement therapy. The US FDA’s decision is expected on Feb 28, 2023
- The results showed clinical bleed protection & superiority to prior factor prophylaxis based on an intra-patient comparison & was well-tolerated, inhibitor development to factor VIII was not detected & provides high sustained factor activity levels in the normal to near-normal range
- The company plans for regulatory submission of efanesoctocog alfa in the EU in 2023, based on (XTEND-Kids) pediatric study. The therapy has received BTD, ODD & FTD from the US FDA for hemophilia A
Ref: Globe Newswire | Image: Sanofi
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
